Abeona's Zevaskyn secures timely FDA nod, priced at $3.1 million, with 2025 sales now forecast at $31.6 million and peak U.S. revenue projected at $600 million.
Commodity prices regularly swing 25-30% or more in any given year. When this happens, the financial health of these firms can get dicey very quickly, given the amount of capital investment it requires to run them.
